Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company's management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022.
BTIG hosted events are intended for prospective and existing BTIG clients only. To schedule a meeting with the Company, please contact your BTIG representative.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE:SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company recently consummated the acquisition of VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
917-680-5608
